Ninth IPO filing in 2012 - Hyperion's $57.5m - does not yet signal 'healthy' investment climate
This article was originally published in Scrip
In the third biopharmaceutical initial public offering filed this month, Hyperion Therapeutics said on 13 April that it wants to raise $57.5 million in an IPO to help fund clinical development of Ravicti (glycerol phenylbutyrate) for urea cycle disorders (UCD) and hepatic encephalopathy.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.